These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 21273305

  • 1. KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferation.
    Lee YN, Brandal S, Noel P, Wentzel E, Mendell JT, McDevitt MA, Kapur R, Carter M, Metcalfe DD, Takemoto CM.
    Blood; 2011 Mar 31; 117(13):3629-40. PubMed ID: 21273305
    [Abstract] [Full Text] [Related]

  • 2. Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation.
    Nakagomi N, Hirota S.
    Lab Invest; 2007 Apr 31; 87(4):365-71. PubMed ID: 17259998
    [Abstract] [Full Text] [Related]

  • 3. The adaptor 3BP2 is required for KIT receptor expression and human mast cell survival.
    Ainsua-Enrich E, Serrano-Candelas E, Álvarez-Errico D, Picado C, Sayós J, Rivera J, Martín M.
    J Immunol; 2015 May 01; 194(9):4309-18. PubMed ID: 25810396
    [Abstract] [Full Text] [Related]

  • 4. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit.
    Akin C, Brockow K, D'Ambrosio C, Kirshenbaum AS, Ma Y, Longley BJ, Metcalfe DD.
    Exp Hematol; 2003 Aug 01; 31(8):686-92. PubMed ID: 12901973
    [Abstract] [Full Text] [Related]

  • 5. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit.
    Verstovsek S, Akin C, Manshouri T, Quintás-Cardama A, Huynh L, Manley P, Tefferi A, Cortes J, Giles FJ, Kantarjian H.
    Leuk Res; 2006 Nov 01; 30(11):1365-70. PubMed ID: 16797704
    [Abstract] [Full Text] [Related]

  • 6. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.
    Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD.
    Blood; 2004 Apr 15; 103(8):3222-5. PubMed ID: 15070706
    [Abstract] [Full Text] [Related]

  • 7. Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412.
    Aichberger KJ, Mayerhofer M, Gleixner KV, Krauth MT, Gruze A, Pickl WF, Wacheck V, Selzer E, Müllauer L, Agis H, Sillaber C, Valent P.
    Blood; 2007 Apr 01; 109(7):3031-41. PubMed ID: 17110460
    [Abstract] [Full Text] [Related]

  • 8. A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors.
    Tanaka A, Konno M, Muto S, Kambe N, Morii E, Nakahata T, Itai A, Matsuda H.
    Blood; 2005 Mar 15; 105(6):2324-31. PubMed ID: 15561889
    [Abstract] [Full Text] [Related]

  • 9. Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing β-catenin signaling.
    Jin B, Ding K, Pan J.
    Mol Cancer Ther; 2014 May 15; 13(5):1217-30. PubMed ID: 24552773
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Involvement of transcription factor encoded by the mi locus in the expression of c-kit receptor tyrosine kinase in cultured mast cells of mice.
    Tsujimura T, Morii E, Nozaki M, Hashimoto K, Moriyama Y, Takebayashi K, Kondo T, Kanakura Y, Kitamura Y.
    Blood; 1996 Aug 15; 88(4):1225-33. PubMed ID: 8695840
    [Abstract] [Full Text] [Related]

  • 18. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.
    Growney JD, Clark JJ, Adelsperger J, Stone R, Fabbro D, Griffin JD, Gilliland DG.
    Blood; 2005 Jul 15; 106(2):721-4. PubMed ID: 15790786
    [Abstract] [Full Text] [Related]

  • 19. Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.
    Aichberger KJ, Gleixner KV, Mirkina I, Cerny-Reiterer S, Peter B, Ferenc V, Kneidinger M, Baumgartner C, Mayerhofer M, Gruze A, Pickl WF, Sillaber C, Valent P.
    Blood; 2009 Dec 17; 114(26):5342-51. PubMed ID: 19850739
    [Abstract] [Full Text] [Related]

  • 20. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
    Gleixner KV, Mayerhofer M, Sonneck K, Gruze A, Samorapoompichit P, Baumgartner C, Lee FY, Aichberger KJ, Manley PW, Fabbro D, Pickl WF, Sillaber C, Valent P.
    Haematologica; 2007 Nov 17; 92(11):1451-9. PubMed ID: 18024392
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.